메뉴 건너뛰기




Volumn 72, Issue 5, 2013, Pages 935-952

Histones and lung cancer: Are the histone deacetylases a promising therapeutic target?

Author keywords

Anticancer agents; Epigenetic events; Histone deacetylase inhibitors; Lung cancer

Indexed keywords

APICIDIN; ATORVASTATIN; BELINOSTAT; BEXAROTENE; BOMBESIN; BUDESONIDE; CG 0006; CG 006; CISPLATIN; DACINOSTAT; ENTINOSTAT; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GENISTEIN; HISTONE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; KD 5170; MOCETINOSTAT; NAVITOCLAX; PACLITAXEL; PANOBINOSTAT; ROMIDEPSIN; SARACATINIB; TACEDINALINE; TRICHOSTATIN A; TRIPEPTIDE; TYROSERVATIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VORINOSTAT; ANTINEOPLASTIC AGENT; TUMOR PROTEIN;

EID: 84887182613     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2223-9     Document Type: Review
Times cited : (34)

References (76)
  • 1
    • 84855792427 scopus 로고    scopus 로고
    • Cancer statistics 2012
    • 10.3322/caac.20138 22237781 10.3322/caac.20138
    • Siegel R, Naishadham D, Jemal A (2012) Cancer statistics 2012. CA Cancer J Clin 62:10-29. doi: 10.3322/caac.20138
    • (2012) CA Cancer J Clin , vol.62 , pp. 10-29
    • Siegel, R.1    Naishadham, D.2    Jemal, A.3
  • 3
    • 77957743500 scopus 로고    scopus 로고
    • The Biology of Lung Cancer, Thoracic Malignancies, Chapter 6. European Respiratory Society
    • doi: 10.1183/1025448x.00044006
    • Lawson MH, Eisen T (2009) The biology of lung cancer, thoracic malignancies, chapter 6. European Respiratory Society. Monograph 44:88-105. doi: 10.1183/1025448x.00044006
    • (2009) Monograph , vol.44 , pp. 88-105
    • Lawson, M.H.1    Eisen, T.2
  • 5
    • 33748451151 scopus 로고    scopus 로고
    • Anticancer activities of histone deacetylase inhibitors
    • DOI 10.1038/nrd2133, PII NRD2133
    • Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5(9):769-784. doi: 10.1038/nrd2133 (Pubitemid 44348499)
    • (2006) Nature Reviews Drug Discovery , vol.5 , Issue.9 , pp. 769-784
    • Bolden, J.E.1    Peart, M.J.2    Johnstone, R.W.3
  • 6
    • 38449100788 scopus 로고    scopus 로고
    • Expression profile of class i histone deacetylases in human cancer tissues
    • 17786334 1:CAS:528:DC%2BD2sXhtFygu7vK
    • Nakagawa M, Oda Y, Eguchi T, Aishima S, Yao T, Hosoi F et al (2007) Expression profile of class I histone deacetylases in human cancer tissues. Oncol Rep 18(4):769-774
    • (2007) Oncol Rep , vol.18 , Issue.4 , pp. 769-774
    • Nakagawa, M.1    Oda, Y.2    Eguchi, T.3    Aishima, S.4    Yao, T.5    Hosoi, F.6
  • 7
    • 79951713773 scopus 로고    scopus 로고
    • Protected from the inside: Endogenous histone deacetylase inhibitors and the road to cancer
    • 10.1016/j.bbcan.2011.01.002 21277938
    • Di Marcotullio L, Canettieri G, Infante P, Greco A, Gulino A (2011) Protected from the inside: endogenous histone deacetylase inhibitors and the road to cancer. Biochim Biophys Acta 1815(2):241-252. doi: 10.1016/j.bbcan.2011. 01.002
    • (2011) Biochim Biophys Acta , vol.1815 , Issue.2 , pp. 241-252
    • Di Marcotullio, L.1    Canettieri, G.2    Infante, P.3    Greco, A.4    Gulino, A.5
  • 8
    • 34247373911 scopus 로고    scopus 로고
    • Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer
    • DOI 10.1038/sj.onc.1210041, PII 1210041
    • Zhong S, Fields CR, Su N, Pan YX, Robertson KD (2007) Pharmacologic inhibition of epigenetic modifications, coupled with gene expression profiling, reveals novel targets of aberrant DNA methylation and histone deacetylation in lung cancer. Oncogene 26(18):2621-3410. doi: 1038/sj.onc.1210041 (Pubitemid 46632003)
    • (2007) Oncogene , vol.26 , Issue.18 , pp. 2621-2634
    • Zhong, S.1    Fields, C.R.2    Su, N.3    Pan, Y.-X.4    Robertson, K.D.5
  • 10
    • 51049090194 scopus 로고    scopus 로고
    • Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: Development of a molecular predictive model
    • 10.1158/1535-7163.MCT-07-2140 18606719 1:CAS:528:DC%2BD1cXoslCgtbY%3D 10.1158/1535-7163.MCT-07-2140
    • Miyanaga A, Gemma A, Noro R, Kataoka K, Matsuda K, Nara M et al (2008) Antitumor activity of histone deacetylase inhibitors in non-small cell lung cancer cells: development of a molecular predictive model. Mol Cancer Ther 7:1923-1930. doi: 10.1158/1535-7163.MCT-07-2140
    • (2008) Mol Cancer Ther , vol.7 , pp. 1923-1930
    • Miyanaga, A.1    Gemma, A.2    Noro, R.3    Kataoka, K.4    Matsuda, K.5    Nara, M.6
  • 11
    • 0035866353 scopus 로고    scopus 로고
    • DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors
    • Zhu WG, Lakshmanan RR, Beal MD, Otterson GA (2001) DNA methyltransferase inhibition enhances apoptosis induced by histone deacetylase inhibitors. Cancer Res 61(4):1327-1333 (Pubitemid 34292551)
    • (2001) Cancer Research , vol.61 , Issue.4 , pp. 1327-1333
    • Zhu, W.-G.1    Lakshmanan, R.R.2    Beal, M.D.3    Otterson, G.A.4
  • 12
    • 77954024844 scopus 로고    scopus 로고
    • HDAC inhibitor-mediated radiosensitization in human carcinoma cells: A general phenomenon?
    • 1:CAS:528:DC%2BC3cXos1Gitro%3D 10.1269/jrr.09115
    • Kim IA, Kim IH, Kim HJ, Chie EK, Kim JS (2010) HDAC inhibitor-mediated radiosensitization in human carcinoma cells: a general phenomenon? Radiat Res 51:257-263
    • (2010) Radiat Res , vol.51 , pp. 257-263
    • Kim, I.A.1    Kim, I.H.2    Kim, H.J.3    Chie, E.K.4    Kim, J.S.5
  • 13
    • 67349201377 scopus 로고    scopus 로고
    • Targeting tumor angiogenesis with histone deacetylase inhibitors
    • 10.1016/j.canlet.2008.11.012 19111391 1:CAS:528:DC%2BD1MXmsF2jt74%3D 10.1016/j.canlet.2008.11.012
    • Ellis L, Hammers H, Pili R (2009) Targeting tumor angiogenesis with histone deacetylase inhibitors. Cancer Lett 280(2):145-153. doi: 10.1016/j.canlet.2008.11.012
    • (2009) Cancer Lett , vol.280 , Issue.2 , pp. 145-153
    • Ellis, L.1    Hammers, H.2    Pili, R.3
  • 14
    • 33744938927 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors suppress the inducibility of nuclear factor-κB by tumor necrosis factor-α receptor-1 down-regulation
    • DOI 10.1158/0008-5472.CAN-05-4225
    • Imre G, Gekeler V, Leja A, Beckers T, Boehm M (2006) Histone deacetylase inhibitors suppress the inducibility of nuclear factor-κΒ by tumor necrosis factor-α receptor-1 down-regulation. Cancer Res 66:5409-5418. doi: 10.1158/0008-5472.CAN-05-4225 (Pubitemid 43844968)
    • (2006) Cancer Research , vol.66 , Issue.10 , pp. 5409-5418
    • Imre, G.1    Gekeler, V.2    Leja, A.3    Beckers, T.4    Boehm, M.5
  • 15
    • 34047218122 scopus 로고    scopus 로고
    • HDAC inhibitors as anti-inflammatory agents
    • DOI 10.1038/sj.bjp.0707166, PII 0707166
    • Adcock IM (2007) HDAC as anti-inflammatory agents. Br J Pharmacol 150(7):829-831. doi: 10.1038/sj.bjp.0707166 (Pubitemid 46536629)
    • (2007) British Journal of Pharmacology , vol.150 , Issue.7 , pp. 829-831
    • Adcock, I.M.1
  • 16
    • 84859434875 scopus 로고    scopus 로고
    • Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer
    • 10.1016/j.lungcan.2011.10.012 22078727 10.1016/j.lungcan.2011.10.012
    • Jeon HS, Lee SY, Lee EJ, Yun SC, Cha EJ, Choi E et al (2012) Combining microRNA-449a/b with a HDAC inhibitor has a synergistic effect on growth arrest in lung cancer. Lung Cancer 76(2):171-176. doi: 10.1016/j.lungcan.2011.10.012
    • (2012) Lung Cancer , vol.76 , Issue.2 , pp. 171-176
    • Jeon, H.S.1    Lee, S.Y.2    Lee, E.J.3    Yun, S.C.4    Cha, E.J.5    Choi, E.6
  • 17
    • 84867033832 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation
    • 10.1002/ijc.27509 22362554 1:CAS:528:DC%2BC38XksFCksrw%3D 10.1002/ijc.27509
    • Oh SH, Whang YM, Min HY, Han SH, Kang JH, Song KH et al (2012) Histone deacetylase inhibitors enhance the apoptotic activity of insulin-like growth factor binding protein-3 by blocking PKC-induced IGFBP-3 degradation. Int J Cancer 131:2253-2263. doi: 10.1002/ijc.27509
    • (2012) Int J Cancer , vol.131 , pp. 2253-2263
    • Oh, S.H.1    Whang, Y.M.2    Min, H.Y.3    Han, S.H.4    Kang, J.H.5    Song, K.H.6
  • 18
    • 33745822415 scopus 로고    scopus 로고
    • Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation
    • DOI 10.1593/neo.05823
    • Ziauddin MF, Yeow WS, Maxhimer JB, Baras A, Chua A, Reddy RM et al (2006) Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation. Neoplasia 8(6):446-457. doi: 10.1593/neo.05823 (Pubitemid 44035328)
    • (2006) Neoplasia , vol.8 , Issue.6 , pp. 446-457
    • Ziauddin, M.F.1    Yeow, W.-S.2    Maxhimer, J.B.3    Baras, A.4    Chua, A.5    Reddy, R.M.6    Tsai, W.7    Cole Jr., G.W.8    Schrump, D.S.9    Nguyen, D.M.10
  • 19
    • 40749117604 scopus 로고    scopus 로고
    • New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity
    • DOI 10.1016/j.bmcl.2008.02.007, PII S0960894X08001753
    • Perrino E, Cappelletti G, Tazzari V, Giavini E, Del Soldato P, Sparatore A (2008) New sulfurated derivatives of valproic acid with enhanced histone deacetylase inhibitory activity. Bioorg Med Chem Lett 18(6):1893-1897. doi: 10.1016/j.bmcl.2008.02.007 (Pubitemid 351380898)
    • (2008) Bioorganic and Medicinal Chemistry Letters , vol.18 , Issue.6 , pp. 1893-1897
    • Perrino, E.1    Cappelletti, G.2    Tazzari, V.3    Giavini, E.4    Soldato, P.D.5    Sparatore, A.6
  • 20
    • 63149096835 scopus 로고    scopus 로고
    • The anticancer effect of histone deacetylase inhibitors and combination with the cytotoxic agents in lung cancer cells: Biological analyses for future clinical application
    • 19305113 10.1272/jnms.76.44
    • Noro R, Miyanaga A, Shimokawa T, Kuribayashi H, Mizutani H, Minegishi Y et al (2009) The anticancer effect of histone deacetylase inhibitors and combination with the cytotoxic agents in lung cancer cells: biological analyses for future clinical application. J Nippon Med Sch 76(1):44-46
    • (2009) J Nippon Med Sch , vol.76 , Issue.1 , pp. 44-46
    • Noro, R.1    Miyanaga, A.2    Shimokawa, T.3    Kuribayashi, H.4    Mizutani, H.5    Minegishi, Y.6
  • 21
    • 79960574987 scopus 로고    scopus 로고
    • Energy metabolism in H460 lung cancer cells: Effects of histone deacetylas inhibitors
    • 10.1371/journal.pone.0022264 21789245 10.1371/journal.pone.0022264
    • Amoêdo ND, Rodrigues MF, Pezzuto P, Galina A, da Costa RM, de Almeida FC et al (2011) Energy metabolism in H460 lung cancer cells: effects of histone deacetylas inhibitors. PLoS ONE 6(7):e22264. doi: 10.1371/journal.pone. 0022264
    • (2011) PLoS ONE , vol.6 , Issue.7 , pp. 22264
    • Amoêdo, N.D.1    Rodrigues, M.F.2    Pezzuto, P.3    Galina, A.4    Da Costa, R.M.5    De Almeida, F.C.6
  • 22
    • 79952207890 scopus 로고    scopus 로고
    • KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib
    • 10.3892/or.2011.1160 21271222 1:CAS:528:DC%2BC3MXksFWltLY%3D
    • Kurtze I, Sonnemann J, Beck JF (2011) KRAS-mutated non-small cell lung cancer cells are responsive to either co-treatment with erlotinib or gefitinib and histone deacetylase inhibitors or single treatment with lapatinib. Oncol Rep 25(4):1021-1029. doi: 10.3892/or.2011.1160
    • (2011) Oncol Rep , vol.25 , Issue.4 , pp. 1021-1029
    • Kurtze, I.1    Sonnemann, J.2    Beck, J.F.3
  • 24
    • 34548700155 scopus 로고    scopus 로고
    • The HDAC Inhibitor Trichostatin A Inhibits Growth of Small Cell Lung Cancer Cells
    • DOI 10.1016/j.jss.2006.12.555, PII S0022480406011802
    • Platta CS, Greenblatt DY, Kunnimalaiyaan M, Chen H (2007) The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J Surg Res 142(2):219-226. doi: 10.1016/j.jss.2006.12.555 (Pubitemid 47418819)
    • (2007) Journal of Surgical Research , vol.142 , Issue.2 , pp. 219-226
    • Platta, C.S.1    Greenblatt, D.Y.2    Kunnimalaiyaan, M.3    Chen, H.4
  • 25
    • 71249163430 scopus 로고    scopus 로고
    • Conserved responses to trichostatin A in rodent lungs exposed to endotoxin or stretch
    • 10.1016/j.pupt.2009.08.005 19744573 1:CAS:528:DC%2BD1MXhtlCnu7bM 10.1016/j.pupt.2009.08.005
    • Dombrowsky H, Barrenschee M, Kunze M, Uhlig S (2009) Conserved responses to trichostatin A in rodent lungs exposed to endotoxin or stretch. Pulm Pharmacol Ther 22(6):593-602. doi: 10.1016/j.pupt.2009.08.005
    • (2009) Pulm Pharmacol Ther , vol.22 , Issue.6 , pp. 593-602
    • Dombrowsky, H.1    Barrenschee, M.2    Kunze, M.3    Uhlig, S.4
  • 26
    • 68149170764 scopus 로고    scopus 로고
    • Sensitization to γ-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells
    • 19270532 1:CAS:528:DC%2BD1MXovFOnsbs%3D 10.4161/cbt.8.9.8143
    • Zhang F, Zhang T, Teng ZH, Zhang R, Wang JB, Mei QB (2009) Sensitization to γ-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells. Cancer Biol Ther 8(9):823-831
    • (2009) Cancer Biol Ther , vol.8 , Issue.9 , pp. 823-831
    • Zhang, F.1    Zhang, T.2    Teng, Z.H.3    Zhang, R.4    Wang, J.B.5    Mei, Q.B.6
  • 27
    • 80051788362 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation
    • 10.1097/JTO.0b013e318220caff 21642861 10.1097/JTO.0b013e318220caff
    • Seo SK, Jin HO, Woo SH, Kim YS, An S, Lee JH, Hong SI, Lee KH, Choe TB, Park IC (2011) Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation. J Thorac Oncol 6(8):1313-1319. doi: 10.1097/JTO. 0b013e318220caff
    • (2011) J Thorac Oncol , vol.6 , Issue.8 , pp. 1313-1319
    • Seo, S.K.1    Jin, H.O.2    Woo, S.H.3    Kim, Y.S.4    An, S.5    Lee, J.H.6    Hong, S.I.7    Lee, K.H.8    Choe, T.B.9    Park, I.C.10
  • 28
    • 84873261115 scopus 로고    scopus 로고
    • Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells
    • 10.1002/mc.21846 22121107 1:CAS:528:DC%2BC3MXlsFGqtrg%3D 10.1002/mc.21846
    • Wang X, Li G, Wang A, Zhang Z, Merchan JR, Halmos B (2011) Combined histone deacetylase and cyclooxygenase inhibition achieves enhanced antiangiogenic effects in lung cancer cells. Mol Carcinog 52(3):218-228. doi: 10.1002/mc.21846
    • (2011) Mol Carcinog , vol.52 , Issue.3 , pp. 218-228
    • Wang, X.1    Li, G.2    Wang, A.3    Zhang, Z.4    Merchan, J.R.5    Halmos, B.6
  • 29
    • 84857716200 scopus 로고    scopus 로고
    • WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors
    • 10.1038/labinvest.2011.187 22157722 1:CAS:528:DC%2BC38XjtFOjtbY%3D 10.1038/labinvest.2011.187
    • Sakuma Y, Yamazaki Y, Nakamura Y, Yoshihara M, Matsukuma S, Nakayama H, Yokose T, Kameda Y, Koizume S, Miyagi Y (2012) WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors. Lab Invest 92(3):371-383. doi: 10.1038/labinvest.2011.187
    • (2012) Lab Invest , vol.92 , Issue.3 , pp. 371-383
    • Sakuma, Y.1    Yamazaki, Y.2    Nakamura, Y.3    Yoshihara, M.4    Matsukuma, S.5    Nakayama, H.6    Yokose, T.7    Kameda, Y.8    Koizume, S.9    Miyagi, Y.10
  • 30
    • 43749087604 scopus 로고    scopus 로고
    • Combinatorial action of the HDAC inhibitor trichostatin A and etoposide induces caspase-mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells
    • DOI 10.1038/sj.onc.1210976, PII 1210976
    • Hajji N, Wallenborg K, Vlachos P, Nyman U, Hermanson O, Joseph B (2008) Combinatorial action of the HDAC inhibitor trichostatin A and etoposide -mediated AIF-dependent apoptotic cell death in non-small cell lung carcinoma cells. Oncogene 27(22):3134-3144. doi: 10.1038/sj.onc.1210976 (Pubitemid 351693171)
    • (2008) Oncogene , vol.27 , Issue.22 , pp. 3134-3144
    • Hajji, N.1    Wallenborg, K.2    Vlachos, P.3    Nyman, U.4    Hermanson, O.5    Joseph, B.6
  • 31
    • 33646871234 scopus 로고    scopus 로고
    • Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation
    • DOI 10.1385/JMN:28:3:231
    • Moody TW, Nakagawa T, Kang Y, Jakowlew S, Chan D, Jensen RT (2006) Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation. J Mol Neurosci 28(3):231-238. doi: 10.1385/JMN:28:3:231 (Pubitemid 43780315)
    • (2006) Journal of Molecular Neuroscience , vol.28 , Issue.3 , pp. 231-238
    • Moody, T.W.1    Nakagawa, T.2    Kang, Y.3    Jakowlew, S.4    Chan, D.5    Jensen, R.T.6
  • 32
    • 74149087388 scopus 로고    scopus 로고
    • Genistein and b-carotene enhance the growth-inhibitory effect of trichostatin A in A549 cells
    • 10.1007/s00394-009-0044-8 19639378 1:CAS:528:DC%2BC3cXjsVSgtA%3D%3D 10.1007/s00394-009-0044-8
    • Shiau RJ, Chen KY, Wen YD, Chuang CH, Yeh SL (2010) Genistein and b-carotene enhance the growth-inhibitory effect of trichostatin A in A549 cells. Eur J Nutr 49(1):19-25. doi: 10.1007/s00394-009-0044-8
    • (2010) Eur J Nutr , vol.49 , Issue.1 , pp. 19-25
    • Shiau, R.J.1    Chen, K.Y.2    Wen, Y.D.3    Chuang, C.H.4    Yeh, S.L.5
  • 33
    • 78649607708 scopus 로고    scopus 로고
    • Effects of tyroservatide on histone acetylation in lung carcinoma cells
    • 10.1002/ijc.25346 20309941 1:CAS:528:DC%2BC3cXhsVGrurrN 10.1002/ijc.25346
    • Xu Q, Lu R, Zhu ZF, Lv JQ, Wang LJ, Zhang W, Hu JW, Meng J, Lin G, Yao Z (2011) Effects of tyroservatide on histone acetylation in lung carcinoma cells. Int J Cancer 128(2):460-472. doi: 10.1002/ijc.25346
    • (2011) Int J Cancer , vol.128 , Issue.2 , pp. 460-472
    • Xu, Q.1    Lu, R.2    Zhu, Z.F.3    Lv, J.Q.4    Wang, L.J.5    Zhang, W.6    Hu, J.W.7    Meng, J.8    Lin, G.9    Yao, Z.10
  • 34
    • 68849110181 scopus 로고    scopus 로고
    • The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer
    • 10.1158/1535-7163.MCT-09-0138 19671764 1:CAS:528:DC%2BD1MXpvFCnu7g%3D 10.1158/1535-7163.MCT-09-0138
    • Crisanti MC, Wallace AF, Kapoor V, Vandermeers F, Dowling ML, Pereira LP, Coleman K, Campling BG, Fridlender ZG, Kao GD, Albelda SM (2009) The HDAC inhibitor panobinostat (LBH589) inhibits mesothelioma and lung cancer cells in vitro and in vivo with particular efficacy for small cell lung cancer. Mol Cancer Ther 8(8):2221-2231. doi: 10.1158/1535-7163.MCT-09-0138
    • (2009) Mol Cancer Ther , vol.8 , Issue.8 , pp. 2221-2231
    • Crisanti, M.C.1    Wallace, A.F.2    Kapoor, V.3    Vandermeers, F.4    Dowling, M.L.5    Pereira, L.P.6    Coleman, K.7    Campling, B.G.8    Fridlender, Z.G.9    Kao, G.D.10    Albelda, S.M.11
  • 35
    • 34748840882 scopus 로고    scopus 로고
    • Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells
    • DOI 10.1158/1535-7163.MCT-06-0761
    • Edwards A, Li J, Atadja P, Bhalla K, Haura EB (2007) Effect of the histone deacetylase inhibitor LBH589 against epidermal growth factor receptor-dependent human lung cancer cells. Mol Cancer Ther 6(9):2515-2524. doi: 10.1158/1535-7163.MCT-06-0761 (Pubitemid 47480417)
    • (2007) Molecular Cancer Therapeutics , vol.6 , Issue.9 , pp. 2515-2524
    • Edwards, A.1    Li, J.2    Atadja, P.3    Bhalla, K.4    Haura, E.B.5
  • 36
    • 65649134414 scopus 로고    scopus 로고
    • Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines
    • 10.1097/JTO.0b013e318194fae7 19179890 10.1097/JTO.0b013e318194fae7
    • Zhang W, Peyton M, Xie Y, Soh J, Minna JD, Gazdar AF, Frenkel EP (2009) Histone deacetylase inhibitor romidepsin enhances anti-tumor effect of erlotinib in non-small cell lung cancer (NSCLC) cell lines. J Thorac Oncol 4(2):161-166. doi: 10.1097/JTO.0b013e318194fae7
    • (2009) J Thorac Oncol , vol.4 , Issue.2 , pp. 161-166
    • Zhang, W.1    Peyton, M.2    Xie, Y.3    Soh, J.4    Minna, J.D.5    Gazdar, A.F.6    Frenkel, E.P.7
  • 37
    • 65549122964 scopus 로고    scopus 로고
    • Acetylation of Fox01 activates bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment
    • 19308286 1:CAS:528:DC%2BD1MXjslClurs%3D
    • Yang Y, Zhao Y, Liao W, Yang J, Wu L, Zheng Z, Yu Y, Zhou W, Li L, Feng J, Wang H, Zhu WG (2009) Acetylation of Fox01 activates bim expression to induce apoptosis in response to histone deacetylase inhibitor depsipeptide treatment. Neoplasia 11(4):313-324
    • (2009) Neoplasia , vol.11 , Issue.4 , pp. 313-324
    • Yang, Y.1    Zhao, Y.2    Liao, W.3    Yang, J.4    Wu, L.5    Zheng, Z.6    Yu, Y.7    Zhou, W.8    Li, L.9    Feng, J.10    Wang, H.11    Zhu, W.G.12
  • 38
    • 38949140475 scopus 로고    scopus 로고
    • Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression
    • DOI 10.1016/j.biopha.2007.06.002, PII S0753332207001163
    • Vinodhkumar R, Song YS, Devaki T (2008) Romidepsin (depsipeptide) induced cell cycle arrest, apoptosis and histone hyperacetylation in lung carcinoma cells (A549) are associated with increase in p21 and hypophosphorylated retinoblastoma proteins expression. Biomed Pharmacother 62(2):85-93 (Pubitemid 351215810)
    • (2008) Biomedicine and Pharmacotherapy , vol.62 , Issue.2 , pp. 85-93
    • Radhakrishnan, V.1    Song, Y.-S.2    Thiruvengadam, D.3
  • 39
    • 33846861339 scopus 로고    scopus 로고
    • Depsipeptide a histone deacetlyase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549)
    • DOI 10.1016/j.cbi.2006.12.012, PII S0009279706003620
    • Vinodhkumar R, Song YS, Ravikumar V, Ramakrishnan G, Devaki T (2007) Depsipeptide a histone deacetylase inhibitor down regulates levels of matrix metalloproteinases 2 and 9 mRNA and protein expressions in lung cancer cells (A549). Chem Biol Interact 165(3):220-229 (Pubitemid 46227368)
    • (2007) Chemico-Biological Interactions , vol.165 , Issue.3 , pp. 220-229
    • Vinodhkumar, R.1    Song, Y.-S.2    Ravikumar, V.3    Ramakrishnan, G.4    Devaki, T.5
  • 40
    • 49849106385 scopus 로고    scopus 로고
    • KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo
    • 10.1158/1535-7163.MCT-07-2347 18483295 1:CAS:528:DC%2BD1cXlvFanurc%3D 10.1158/1535-7163.MCT-07-2347
    • Hassig CA, Symons KT, Guo X, Nguyen PM, Annable T, Wash PL (2008) KD5170, a novel mercaptoketone-based histone deacetylase inhibitor that exhibits broad spectrum antitumor activity in vitro and in vivo. Mol Cancer Ther 7(5):1054-1065. doi: 10.1158/1535-7163.MCT-07-2347
    • (2008) Mol Cancer Ther , vol.7 , Issue.5 , pp. 1054-1065
    • Hassig, C.A.1    Symons, K.T.2    Guo, X.3    Nguyen, P.M.4    Annable, T.5    Wash, P.L.6
  • 41
    • 34347261742 scopus 로고    scopus 로고
    • Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells
    • 10.1097/PPO.0b013e318046eedc 17476138 1:CAS:528:DC%2BD2sXmtVGru70%3D 10.1097/PPO.0b013e318046eedc
    • Yu XD, Wang SY, Chen GA, Hou CM, Zhao M, Hong JA, Nguyen DM, Schrump DS (2007) Apoptosis induced by depsipeptide FK228 coincides with inhibition of survival signaling in lung cancer cells. Cancer J 13(2):105-113. doi: 10.1097/PPO.0b013e318046eedc
    • (2007) Cancer J , vol.13 , Issue.2 , pp. 105-113
    • Yu, X.D.1    Wang, S.Y.2    Chen, G.A.3    Hou, C.M.4    Zhao, M.5    Hong, J.A.6    Nguyen, D.M.7    Schrump, D.S.8
  • 42
    • 84855363380 scopus 로고    scopus 로고
    • Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide
    • 10.1038/bjc.2011.532 22158273 1:CAS:528:DC%2BC38XktFCnsg%3D%3D 10.1038/bjc.2011.532
    • Chang J, Varghese DS, Gillam MC, Peyton M, Modi B, Schiltz RL, Girard L, Martinez ED (2012) Differential response of cancer cells to HDAC inhibitors trichostatin A and depsipeptide. Br J Cancer 106(1):116-125. doi: 10.1038/bjc.2011.532
    • (2012) Br J Cancer , vol.106 , Issue.1 , pp. 116-125
    • Chang, J.1    Varghese, D.S.2    Gillam, M.C.3    Peyton, M.4    Modi, B.5    Schiltz, R.L.6    Girard, L.7    Martinez, E.D.8
  • 44
    • 80053207760 scopus 로고    scopus 로고
    • Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non-small cell lung cancers
    • 21678477 1:CAS:528:DC%2BC3MXhtFyqtrnJ 10.1002/jcb.23229
    • Li CT, Hsiao YM, Wu TC, Lin YW, Yeh KT, Ko JL (2011) Vorinostat, SAHA, represses telomerase activity via epigenetic regulation of telomerase reverse transcriptase in non-small cell lung cancers. J Cell Biochem 112(10):3044-3053
    • (2011) J Cell Biochem , vol.112 , Issue.10 , pp. 3044-3053
    • Li, C.T.1    Hsiao, Y.M.2    Wu, T.C.3    Lin, Y.W.4    Yeh, K.T.5    Ko, J.L.6
  • 45
    • 78149491383 scopus 로고    scopus 로고
    • Anti-tumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and retinoic acids
    • 10.1371/journal.pone.0013834 21079797 10.1371/journal.pone.0013834
    • Han S, Fukazawa T, Yamatsuji T, Matsuoka J, Miyachi H, Maeda Y, Durbin M, Naomoto Y (2010) Anti-tumor effect in human lung cancer by a combination treatment of novel histone deacetylase inhibitors: SL142 or SL325 and retinoic acids. PLoS ONE 5(11):e13834. doi: 10.1371/journal.pone.0013834
    • (2010) PLoS ONE , vol.5 , Issue.11 , pp. 13834
    • Han, S.1    Fukazawa, T.2    Yamatsuji, T.3    Matsuoka, J.4    Miyachi, H.5    Maeda, Y.6    Durbin, M.7    Naomoto, Y.8
  • 46
    • 77958043580 scopus 로고    scopus 로고
    • Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells
    • 10.1016/j.bmcl.2010.08.113 20855208 1:CAS:528:DC%2BC3cXhtlSmsLvM 10.1016/j.bmcl.2010.08.113
    • Karelia N, Desai D, Hengst JA, Amin S, Rudrabhatla SV, Yun J (2010) Selenium-containing analogs of SAHA induce cytotoxicity in lung cancer cells. Bioorg Med Chem Lett 20(22):6816-6819. doi: 10.1016/j.bmcl.2010.08.113
    • (2010) Bioorg Med Chem Lett , vol.20 , Issue.22 , pp. 6816-6819
    • Karelia, N.1    Desai, D.2    Hengst, J.A.3    Amin, S.4    Rudrabhatla, S.V.5    Yun, J.6
  • 47
    • 33644875208 scopus 로고    scopus 로고
    • SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells
    • 1:CAS:528:DC%2BD28XmsFersA%3D%3D
    • Komatsu N, Kawamata N, Takeuchi S, Yin D, Chien W, Miller CW, Koeffler HP (2006) SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Re 15(1):187-191
    • (2006) Oncol Re , vol.15 , Issue.1 , pp. 187-191
    • Komatsu, N.1    Kawamata, N.2    Takeuchi, S.3    Yin, D.4    Chien, W.5    Miller, C.W.6    Koeffler, H.P.7
  • 48
    • 77954146994 scopus 로고    scopus 로고
    • Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21waf1/cip1 expression
    • 20384633 1:CAS:528:DC%2BC3cXns1Sks7Y%3D 10.1111/j.1349-7006.2010.01559.x
    • Noro R, Miyanaga A, Minegishi Y, Okano T, Seike M, Soeno C (2010) Histone deacetylase inhibitor enhances sensitivity of non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of thymidylate synthase expression and up-regulation of p21waf/cip1 expression. Cancer Sci 101(6):1424-1430
    • (2010) Cancer Sci , vol.101 , Issue.6 , pp. 1424-1430
    • Noro, R.1    Miyanaga, A.2    Minegishi, Y.3    Okano, T.4    Seike, M.5    Soeno, C.6
  • 49
    • 80054718842 scopus 로고    scopus 로고
    • Prevention of mouse lung tumors by combinations of chemopreventive agents using concurrent and sequential administration
    • Casto BC, Pereira MA (2011) Prevention of mouse lung tumors by combinations of chemopreventive agents using concurrent and sequential administration. Anticancer Res (10): 3279-3284
    • (2011) Anticancer Res , Issue.10 , pp. 3279-3284
    • Casto, B.C.1    Pereira, M.A.2
  • 50
    • 81255175566 scopus 로고    scopus 로고
    • Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide
    • 10.1016/j.taap.2011.08.018
    • Chien CW, Yao JH, Chang SY, Lee PC, Lee TC (2011) Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide. Toxicol Appl Pharmacol 57(1):59-66
    • (2011) Toxicol Appl Pharmacol , vol.57 , Issue.1 , pp. 59-66
    • Chien, C.W.1    Yao, J.H.2    Chang, S.Y.3    Lee, P.C.4    Lee, T.C.5
  • 52
    • 0036746906 scopus 로고    scopus 로고
    • Antineoplastic action of 5-aza-20-deoxycytidine and phenylbutyrate on human lung carcinoma cells
    • 12394273 1:CAS:528:DC%2BD38XotVCms7o%3D 10.1097/00001813-200209000-00013
    • Boivin AJ, Momparler LF, Hurtubise A, Momparler RL (2002) Antineoplastic action of 5-aza-20-deoxycytidine and phenylbutyrate on human lung carcinoma cells. Anticancer Drugs 13(8):869-874
    • (2002) Anticancer Drugs , vol.13 , Issue.8 , pp. 869-874
    • Boivin, A.J.1    Momparler, L.F.2    Hurtubise, A.3    Momparler, R.L.4
  • 53
    • 84862907563 scopus 로고    scopus 로고
    • Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models
    • 22279574 1:CAS:528:DC%2BC38XhvVyrsL8%3D 10.1371/journal.pone.0030240
    • Shieh JM, Wei TT, Tang YA, Huang SM, Wen WL, Chen MY, Cheng HC, Salunke SB, Chen CS, Lin P, Chen CT, Wang YC (2012) Mitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse models. PLoS ONE 7(1):e30240
    • (2012) PLoS ONE , vol.7 , Issue.1 , pp. 30240
    • Shieh, J.M.1    Wei, T.T.2    Tang, Y.A.3    Huang, S.M.4    Wen, W.L.5    Chen, M.Y.6    Cheng, H.C.7    Salunke, S.B.8    Chen, C.S.9    Lin, P.10    Chen, C.T.11    Wang, Y.C.12
  • 54
    • 70349126890 scopus 로고    scopus 로고
    • A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways
    • 10.1097/CAD.0b013e3283300a0f 19644355 1:CAS:528:DC%2BD1MXhtVOis77L 10.1097/CAD.0b013e3283300a0f
    • Hwang JJ, Kim YS, Kim MJ, Jang S, Lee JH, Choi J, Ro S, Hyun YL, Lee JS, Kim CS (2009) A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways. Anticancer Drugs 20(9):815-821. doi: 10.1097/CAD.0b013e3283300a0f
    • (2009) Anticancer Drugs , vol.20 , Issue.9 , pp. 815-821
    • Hwang, J.J.1    Kim, Y.S.2    Kim, M.J.3    Jang, S.4    Lee, J.H.5    Choi, J.6    Ro, S.7    Hyun, Y.L.8    Lee, J.S.9    Kim, C.S.10
  • 56
    • 85047686704 scopus 로고    scopus 로고
    • Combination of HDAC and topoisomerase inhibitors in small cell lung cancer
    • 10.4161/cbt.19848 22441819 1:CAS:528:DC%2BC38Xht1ensLfJ 10.4161/cbt.19848
    • Gray J, Cubitt CL, Zhang S, Chiappori A (2012) Combination of HDAC and topoisomerase inhibitors in small cell lung cancer. Cancer Biol Ther 13(8):614-622. doi: 10.4161/cbt.19848
    • (2012) Cancer Biol Ther , vol.13 , Issue.8 , pp. 614-622
    • Gray, J.1    Cubitt, C.L.2    Zhang, S.3    Chiappori, A.4
  • 57
    • 77958572898 scopus 로고    scopus 로고
    • Novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer
    • 10.1371/journal.pone.0012417 20856855 10.1371/journal.pone.0012417
    • Tang YA, Wen WL, Chang JW, Wei TT, Tan YH, Salunke S, Chen CT, Chen CS, Wang YC (2010) Novel histone deacetylase inhibitor exhibits antitumor activity via apoptosis induction, F-actin disruption and gene acetylation in lung cancer. PLoS ONE 5(9):e12417. doi: 10.1371/journal.pone.0012417
    • (2010) PLoS ONE , vol.5 , Issue.9 , pp. 12417
    • Tang, Y.A.1    Wen, W.L.2    Chang, J.W.3    Wei, T.T.4    Tan, Y.H.5    Salunke, S.6    Chen, C.T.7    Chen, C.S.8    Wang, Y.C.9
  • 58
    • 67649335394 scopus 로고    scopus 로고
    • Advances in preclinical small molecules for the treatment of NSCLC
    • 10.1517/13543770902967674 19456275 1:CAS:528:DC%2BD1MXmsVGjtL8%3D 10.1517/13543770902967674
    • Zhang Q, Feng W, Zhou H, Yan B (2009) Advances in preclinical small molecules for the treatment of NSCLC. Expert Opin Ther Pat 19(6):731-751. doi: 10.1517/13543770902967674
    • (2009) Expert Opin Ther Pat , vol.19 , Issue.6 , pp. 731-751
    • Zhang, Q.1    Feng, W.2    Zhou, H.3    Yan, B.4
  • 59
    • 63149187235 scopus 로고    scopus 로고
    • Rescue of major histocompatibility - DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor
    • 19252299 1:CAS:528:DC%2BD1MXmsVaru7g%3D 10.1248/bpb.32.480
    • Niesen MI, Blanck G (2009) Rescue of major histocompatibility - DR surface expression in retinoblastoma-defective, non-small cell lung carcinoma cells by the MS-275 histone deacetylase inhibitor. Biol Pharm Bull 32(3):480-482
    • (2009) Biol Pharm Bull , vol.32 , Issue.3 , pp. 480-482
    • Niesen, M.I.1    Blanck, G.2
  • 60
    • 78751512281 scopus 로고    scopus 로고
    • Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model
    • 10.1158/0008-5472.CAN-10-3184 21224363 1:CAS:528:DC%2BC3MXlsFKmug%3D%3D 10.1158/0008-5472.CAN-10-3184
    • Belinsky SA, Grimes MJ, Picchi MA, Mitchell HD, Stidley CA, Tesfaigzi Y (2011) Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res 71(2):454-462. doi: 10.1158/0008-5472.CAN-10-3184
    • (2011) Cancer Res , vol.71 , Issue.2 , pp. 454-462
    • Belinsky, S.A.1    Grimes, M.J.2    Picchi, M.A.3    Mitchell, H.D.4    Stidley, C.A.5    Tesfaigzi, Y.6
  • 61
    • 34250805910 scopus 로고    scopus 로고
    • Histone deacetylase inhibitor NVP-LAQ824 sensitizes human nonsmall cell lung cancer to the cytotoxic effects of ionizing radiation
    • DOI 10.1097/CAD.0b013e3280b10d57, PII 0000181320070800000006
    • Cuneo KC, Fu A, Osusky K, Huamani J, Hallahan DE, Geng L (2007) Histone deacetylase inhibitor NVP-LAQ824 sensitizes human non small cell lung cancer to the cytotoxic effects of ionizing radiation. Anticancer Drugs 18(7):793-800 (Pubitemid 46975965)
    • (2007) Anti-Cancer Drugs , vol.18 , Issue.7 , pp. 793-800
    • Cuneo, K.C.1    Fu, A.2    Osusky, K.3    Huamani, J.4    Hallahan, D.E.5    Geng, L.6
  • 62
    • 34547094822 scopus 로고    scopus 로고
    • Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group
    • DOI 10.1002/ijc.22751
    • Beckers T, Burkhardt C, Wieland H, Gimmnich P, Ciossek T, Maier T, Sanders K (2007) Distinct pharmacological properties of second generation HDAC inhibitors with the benzamide or hydroxamate head group. Int J Cancer 121(5):1138-1148 (Pubitemid 47101654)
    • (2007) International Journal of Cancer , vol.121 , Issue.5 , pp. 1138-1148
    • Beckers, T.1    Burkhardt, C.2    Wieland, H.3    Gimmnich, P.4    Ciossek, T.5    Maier, T.6    Sanders, K.7
  • 63
    • 53949087611 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors: The anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex)
    • 10.1007/s10585-008-9179-x 18506586 1:CAS:528:DC%2BD1cXhtlClur3M 10.1007/s10585-008-9179-x
    • Tarasenko N, Nudelman A, Tarasenko I, Entin-Meer M, Hass-Kogan D, Inbal A, Rephaeli A (2008) Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). Clin Exp Metastasis 25(7):703-716. doi: 10.1007/s10585-008-9179-x
    • (2008) Clin Exp Metastasis , vol.25 , Issue.7 , pp. 703-716
    • Tarasenko, N.1    Nudelman, A.2    Tarasenko, I.3    Entin-Meer, M.4    Hass-Kogan, D.5    Inbal, A.6    Rephaeli, A.7
  • 64
    • 79952262759 scopus 로고    scopus 로고
    • Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
    • 10.1007/s13148-010-0012-4 1:CAS:528:DC%2BC3cXhsVeqsrrF 10.1007/s13148-010-0012-4
    • Wagner JM, Hackanson B, Lübbert M, Jung M (2010) Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin Epigenet 1:117-136. doi: 10.1007/s13148-010-0012-4
    • (2010) Clin Epigenet , vol.1 , pp. 117-136
    • Wagner, J.M.1    Hackanson, B.2    Lübbert, M.3    Jung, M.4
  • 65
    • 84856557385 scopus 로고    scopus 로고
    • Phase i study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies
    • 10.1007/s10637-010-9503-6 1:CAS:528:DC%2BC38XotVWjtA%3D%3D 10.1007/s10637-010-9503-6
    • Schneider BJ, Kalemkerian GP, Bradley D, Smith DC, Egorin MJ, Daignault S (2012) Phase I study of vorinostat (suberoylanilide hydroxamic acid, NSC 701852) in combination with docetaxel in patients with advanced and relapsed solid malignancies. Invest New Drug 30(1):249-257. doi: 10.1007/s10637-010-9503- 6
    • (2012) Invest New Drug , vol.30 , Issue.1 , pp. 249-257
    • Schneider, B.J.1    Kalemkerian, G.P.2    Bradley, D.3    Smith, D.C.4    Egorin, M.J.5    Daignault, S.6
  • 66
    • 73449144466 scopus 로고    scopus 로고
    • Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells
    • 10.1002/ijc.24759 19621389 1:CAS:528:DC%2BD1MXhsFGjs7bO 10.1002/ijc.24759
    • Owonikoko TK, Ramalingam SS, Kanterewicz B, Balius TE, Belani CP, Hershberger PA (2010) Vorinostat increases carboplatin and paclitaxel activity in non-small cell lung cancer cells. Int J Cancer 126(3):743-755. doi: 10.1002/ijc.24759
    • (2010) Int J Cancer , vol.126 , Issue.3 , pp. 743-755
    • Owonikoko, T.K.1    Ramalingam, S.S.2    Kanterewicz, B.3    Balius, T.E.4    Belani, C.P.5    Hershberger, P.A.6
  • 67
    • 2942724589 scopus 로고    scopus 로고
    • Histone deacetylase inhibitors: Development as cancer therapy
    • 15171260 1:CAS:528:DC%2BD2cXns1Whs7s%3D 10.1002/0470862637.ch20
    • Marks PA, Richon VM, Kelly WK, Chiao JH, Miller T (2004) Histone deacetylase inhibitors: development as cancer therapy. Novartis Found Symp 259:269-281
    • (2004) Novartis Found Symp , vol.259 , pp. 269-281
    • Marks, P.A.1    Richon, V.M.2    Kelly, W.K.3    Chiao, J.H.4    Miller, T.5
  • 69
    • 73949140461 scopus 로고    scopus 로고
    • Carboplatin and Paclitaxel in combination with either Vorinostat or placebo for first-line therapy of advanced non-small cell lung cancer
    • 10.1200/JCO.2009.24.9094 19933908 1:CAS:528:DC%2BC3cXhtF2ku7c%3D 10.1200/JCO.2009.24.9094
    • Ramalingam SS, Maitland ML, Frankel P, Argiris AE, Koczywas M, Gitlitz B, Thomas S, Espinoza-Delgado I, Vokes EE, Gandara DR, Belani CP (2010) Carboplatin and Paclitaxel in combination with either Vorinostat or placebo for first-line therapy of advanced non-small cell lung cancer. J Clin Oncol 28(1):56-62. doi: 10.1200/JCO.2009.24.9094
    • (2010) J Clin Oncol , vol.28 , Issue.1 , pp. 56-62
    • Ramalingam, S.S.1    Maitland, M.L.2    Frankel, P.3    Argiris, A.E.4    Koczywas, M.5    Gitlitz, B.6    Thomas, S.7    Espinoza-Delgado, I.8    Vokes, E.E.9    Gandara, D.R.10    Belani, C.P.11
  • 70
    • 77951596820 scopus 로고    scopus 로고
    • Updates in non-small cell lung cancer-insights from the 2009 45th annual meeting of the American Society of Clinical Oncology
    • 10.1186/1756-8722-3-18 20433767 10.1186/1756-8722-3-18
    • Mirshahidi HR, Hsueh CT (2010) Updates in non-small cell lung cancer-insights from the 2009 45th annual meeting of the American Society of Clinical Oncology. J Hematol Oncol 3:18. doi: 10.1186/1756-8722-3-18
    • (2010) J Hematol Oncol , vol.3 , pp. 18
    • Mirshahidi, H.R.1    Hsueh, C.T.2
  • 71
    • 50249095068 scopus 로고    scopus 로고
    • Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer
    • 18425418 1:CAS:528:DC%2BD1cXhtVSku7fM 10.1007/s10637-008-9131-6
    • Vansteenkiste J, Van Cutsem E, Dumez H, Chen C, Ricker JL, Randolph SS, Schöffski P (2008) Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer. Invest New Drugs 26(5):483-488
    • (2008) Invest New Drugs , vol.26 , Issue.5 , pp. 483-488
    • Vansteenkiste, J.1    Van Cutsem, E.2    Dumez, H.3    Chen, C.4    Ricker, J.L.5    Randolph, S.S.6    Schöffski, P.7
  • 72
    • 84864004796 scopus 로고    scopus 로고
    • Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy
    • 10.1200/JCO.2011.38.9411 22508830 1:CAS:528:DC%2BC38XhtFCjtrbO 10.1200/JCO.2011.38.9411
    • Witta SE, Jotte RM, Konduri K, Neubauer MA, Spira AI, Ruxer RL, Varella-Garcia M, Bunn PA Jr, Hirsch FR (2012) Randomized phase II trial of erlotinib with and without entinostat in patients with advanced non-small-cell lung cancer who progressed on prior chemotherapy. J Clin Oncol 30(18):2248-2255. doi: 10.1200/JCO.2011.38.9411
    • (2012) J Clin Oncol , vol.30 , Issue.18 , pp. 2248-2255
    • Witta, S.E.1    Jotte, R.M.2    Konduri, K.3    Neubauer, M.A.4    Spira, A.I.5    Ruxer, R.L.6    Varella-Garcia, M.7    Bunn, Jr.P.A.8    Hirsch, F.R.9
  • 73
    • 84655163371 scopus 로고    scopus 로고
    • Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer
    • 10.1158/2159-8290.CD-11-0214 22586682 1:CAS:528:DC%2BC3MXhs1agt7rK 10.1158/2159-8290.CD-11-0214
    • Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM et al (2011) Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 1(7):598-607. doi: 10.1158/2159-8290.CD-11-0214
    • (2011) Cancer Discov , vol.1 , Issue.7 , pp. 598-607
    • Juergens, R.A.1    Wrangle, J.2    Vendetti, F.P.3    Murphy, S.C.4    Zhao, M.5    Coleman, B.6    Sebree, R.7    Rodgers, K.8    Hooker, C.M.9
  • 75
    • 79251559363 scopus 로고    scopus 로고
    • European lung cancer working party (ELCWP). Valproate-doxorubicin: Promising therapy for progressing mesothelioma. A phase II study
    • doi: 10.1183/09031936.00037310 10.1093/annonc/mdm204
    • Scherpereel A, Berghmans T, Lafitte JJ, Colinet B, Richez M, Bonduelle Y, Meert AP, Dhalluin X, Leclercq et al (2011) European lung cancer working party (ELCWP). Valproate-doxorubicin: promising therapy for progressing mesothelioma. A phase II study, Eur Respir J 37(1): 129-135. doi: 10.1183/09031936.00037310 10.1093/annonc/mdm204
    • (2011) Eur Respir J , vol.37 , Issue.1 , pp. 129-135
    • Scherpereel, A.1    Berghmans, T.2    Lafitte, J.J.3    Colinet, B.4    Richez, M.5    Bonduelle, Y.6    Meert, A.P.7    Dhalluin, X.8    Leclercq9
  • 76
    • 50349086621 scopus 로고    scopus 로고
    • The potential role of histone deacetylase inhibitors in the treatment of non-small cell lung cancer
    • 10.1016/j.critrevonc.2008.03.002 18424067 10.1016/j.critrevonc.2008.03. 002
    • Gridelli C, Rossi A, Maione P (2008) The potential role of histone deacetylase inhibitors in the treatment of non-small cell lung cancer. Crit Rev Oncol Hematol 68(1):29-36. doi: 10.1016/j.critrevonc.2008.03.002
    • (2008) Crit Rev Oncol Hematol , vol.68 , Issue.1 , pp. 29-36
    • Gridelli, C.1    Rossi, A.2    Maione, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.